People
Noven Names Purcell as Head of Marketing and Sales
15 July 2019 - - US-based specialty pharmaceutical company Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., has appointed Andrew J. Purcell as Noven's head of marketing and sales, the company said.
In this new role, Purcell will develop and lead Noven's marketing and sales team as Noven prepares for the potential launch and commercialization of HP-3070 (asenapine) transdermal drug delivery system, a new investigational patch product for the treatment of schizophrenia.
A New Drug Application is currently under review by FDA for HP-3070, which was developed by Hisamitsu and, if approved, will be commercialized by Noven in the United States.
Asenapine is a second generation atypical antipsychotic currently available as a sublingual formulation for the treatment of schizophrenia in adults.
HP-3070 is an investigational asenapine-containing Transdermal Drug Delivery System, developed by Hisamitsu Pharmaceutical, to be applied as a patch to the skin for the treatment of schizophrenia.
If approved by the US Food and Drug Administration, HP-3070 may provide a novel treatment option for patients, caregivers, and physicians, as the first and only transdermal patch antipsychotic available for the treatment of schizophrenia in the US A New Drug Application for HP-3070 is under review by the FDA.
The NDA is supported by a robust clinical program, including nine clinical studies, which establish the safety and efficacy profile of HP-3070. The development of HP-3070 represents Noven and Hisamitsu Pharmaceutical's commitment to improving the lives of the community of patients who live with schizophrenia.
Schizophrenia is a severe, chronic psychiatric disease with a heterogeneous course and symptom profile.
The symptoms associated with schizophrenia are disabling and lifelong, and greatly affect a patient's quality of life and social functioning. Symptoms such as hallucinations and delusions usually start between ages 16 and 30.
Schizophrenia presents clinically as negative (affective flattening, social withdrawal, and restriction in the fluency and productivity of thought and speech and in the initiation of goal-directed behavior), positive (delusions, hallucinations, disorganized speech and disorganized or catatonic behaviors) and cognitive symptoms.
Cognitive symptoms such as impairment in sustained attention, impaired executive functioning, and impaired working memory may also be present.
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products.
Noven's mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery.
Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu's US platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world.
Login
Username:

Password: